^
Association details:
| Biomarker: | EGFR exon 19 deletion + EGFR T790M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | EGFR inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The characteristics and clinical outcome of metastatic NSCLC harboring uncommon EGFR mutation at Thailand's tertiary referral center
Published date:
10/09/2018
Excerpt:
The longest OS was 73.6 months in a patient with del19 plus de novo T790M....This study demonstrated the benefit of 1st generation EGFR-TKI was greater than with chemotherapy alone in the patients with uncommon or compound EGFR mutation NSCLC.
